D. Scherrer

发表

RNA sequencing analysis of activated macrophages treated with the anti-HIV ABX464 in intestinal inflammation

L. Manchon, K. Chébli, L. Papon, 2017, Scientific Data.

Long lasting control of viral rebound with a new drug ABX464 targeting Rev – mediated viral RNA biogenesis

M. Wainberg, A. Garcel, Noëlie Campos, 2015, Retrovirology.

Safety, Pharmacokinetics, and Antiviral Activity of a Novel HIV Antiviral, ABX464, in Treatment-Naive HIV-Infected Subjects in a Phase 2 Randomized, Controlled Study

K. Ruxrungtham, D. Scherrer, H. Ehrlich, 2017, Antimicrobial Agents and Chemotherapy.

Pharmacological modulation of LMNA SRSF1-dependent splicing abrogates diet-induced obesity in mice

Carine, D. Scherrer, J. Tazi, 2017, International Journal of Obesity.

Both anti-inflammatory and antiviral properties of novel drug candidate ABX464 are mediated by modulation of RNA splicing

L. Manchon, A. Garcel, Noëlie Campos, 2019, Scientific Reports.

Specific and selective induction of miR-124 in immune cells by the quinoline ABX464: a transformative therapy for inflammatory diseases.

A. Garcel, Noëlie Campos, D. Scherrer, 2020, Drug discovery today.

Safety, tolerability and impact on viral reservoirs of the addition to antiretroviral therapy of ABX464, an investigational antiviral drug, in individuals living with HIV-1: a Phase IIa randomised controlled study

D. Scherrer, H. Ehrlich, J. Tazi, 2019, Journal of virus eradication.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

The Anti-Hiv Candidate Abx464 Dampens Intestinal Inflammation by Triggering Il-22 Production in Activated Macrophages

L. Papon, C. Paul, A. Garcel, 2017, Scientific Reports.

Demonstration of the Antitumor Activity of the iNKT Agonist ABX196, a Novel Enhancer of Cancer Immunotherapy, in Melanoma and Hepatocarcinoma Mouse Models

D. Scherrer, H. Ehrlich, L. Teyton, 2022, Molecular cancer therapeutics.

ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension.

H. Tilg, S. Vermeire, D. Scherrer, 2022, The lancet. Gastroenterology & hepatology.

Pharmacokinetics and tolerability of ABX464, a novel first-in-class compound to treat HIV infection, in healthy HIV-uninfected subjects

D. Scherrer, H. Ehrlich, J. Tazi, 2016, The Journal of antimicrobial chemotherapy.

Randomized Trial of Food Effect on Pharmacokinetic Parameters of ABX464 Administered Orally to Healthy Male Subjects

D. Scherrer, H. Ehrlich, J. Tazi, 2016, Antimicrobial Agents and Chemotherapy.

Safety and efficacy of the miR-124 upregulator ABX464 (obefazimod, 50 and 100 mg per day) in patients with active rheumatoid arthritis and inadequate response to methotrexate and/or anti-TNFα therapy: a placebo-controlled phase II study

D. Scherrer, H. Ehrlich, P. Durez, 2022, Annals of the Rheumatic Diseases.

Both anti-inflammatory and antiviral properties of novel drug candidate ABX464 are mediated by modulation of RNA splicing

L. Manchon, A. Garcel, Noëlie Campos, 2019, Scientific Reports.

Obefazimod: A First-in-class Drug for the Treatment of Ulcerative Colitis.

H. Tilg, S. Vermeire, D. Scherrer, 2023, Journal of Crohn's & colitis.

The Anti-Hiv Candidate Abx464 Dampens Intestinal Inflammation by Triggering Il-22 Production in Activated Macrophages

L. Papon, C. Paul, A. Garcel, 2017, Scientific Reports.

ABX464 (Obefazimod) Upregulates miR-124 to Reduce Proinflammatory Markers in Inflammatory Bowel Diseases

A. Garcel, Noëlie Campos, D. Scherrer, 2022, Clinical and translational gastroenterology.